Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: The German perspective

European Journal of Endocrinology

Volumn 155, Issue 3, 2006, Pages 405-414

  Mernagh, P ^a   Campbell, S ^a   Dietein, M ^b   Luster, M ^c   Mazzaferri, E ^d   Weston, A R ^a  

^a Health Technology Analysts Pty Ltd   (Australia)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN;

ARTICLE; CANCER RISK; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; ECONOMIC EVALUATION; GERMANY; HUMAN; HYPOTHYROIDISM; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; PRIORITY JOURNAL; PROBABILITY; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RADIATION PROTECTION; RISK REDUCTION; SENSITIVITY ANALYSIS; THYROID CANCER; THYROIDECTOMY;

COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; EFFICIENCY; GERMANY; HEALTH STATUS; HUMANS; HYPOTHYROIDISM; IODINE RADIOISOTOPES; MARKOV CHAINS; MODELS, ECONOMIC; MODELS, STATISTICAL; MONTE CARLO METHOD; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RECOMBINANT PROTEINS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN;

EID: 33749057699     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02223     Document Type: Article

References (34)

1. Sweeney DC & Johnston GS. Radioiodine therapy for thyroid cancer. Endocrinology Metabolism Clinics of North America 1995 24 803-839.
2. Dietlein M, Dressler J, Farahati J, Grunwald F, Leisner B, Moser E, Reiners C, Schicha H & Schober O. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2). Nuklearmedizin 2004 43 115-120.
3. Dow KH, Ferrell BR & Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997 7 613-619.
4. LeClere J, Nunez S, Dejax C, Sohmer V & Schvartz C. Quantitative and qualitative consequences of I-T4 suppressive withdrawal 2000. European Association of Nuclear Medicine Congress, Abstract, Paris 2000.
5. Luster M, Felbinger R, Dietlein M & Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005 15 1147-1155.
6. Nijhuis TF, van Weperen W & de Klerk JMH. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschrift voor Nucleaire Geneeskunde 1999 21 98-100.
7. Kovatcheva RD, Hadjieva TD, Kirilov GG & Lozanov BS. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer. Nuclear Medicine Review: Central and Eastern Europe 2004 7 13-19.
8. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C & Pacini F. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer 2005 12 49-64.
9. Robbins RJ, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H, Fleisher M & Larson SM. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 2001 11 865-869.
10. Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, Ghossein R & Michael Tuttle R. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. Journal of Nuclear Medicine 2002 43 1482-1488.
11. Pacini F, Ladenson PW Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M & Reiners C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Journal of Clinical Endocrinology Metabolism 2006 91 926-932.
12. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC & Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. Journal of Clinical Endocrinology Metabolism 2006 91 878-884.
13. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Dreidger A, Kloos RT, Sherman S, Haugen B, Carriere V & Christoph Reiners C. Iodine biokinetics and dosimetry in radioiodine therapy of thryoid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine 2006 47 648-654.
14. Luster M, Sherman ST, Skarulis MC, Reynolds JR, Lassmann M, Hanscheid H & Reiners C. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 2003 30 1371-1377.
15. Menzel C, Kranert WT, Dobert N, Diehl M, Fietz T, Hamscho N, Berner U & Grunwald F. rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of 131I. Journal of Nuclear Medicine 2003 44 1065-1068.
16. Hoefnagel CA, Clarke SE, Fischer M, Chatal JF, Lewington VJ, Nilsson S, Troncone L & Vieira MR. Radionuclide therapy practice and facilities in Europe. EANM Radionuclide Therapy Committee. European Journal of Nuclear Medicine 1999 26 277-282.
17. Venencia CD, Germanier AG, Bustos SR, Giovarnnini AA & Wyse EP. Hospital discharge of patients with thyroid carcinoma treated with 131I. Journal of Nuclear Medicine 2002 43 61-65.
18. Berg G, Lindstedt G, Suurkula M & Jansson S. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. Journal of Endocrinological Investigation 2002 25 44-52.
19. Blamey S, Barraclough B, Delbridge L, Mernagh P, Standfield L & Weston A. Using recombinant human thyroid-stimulating hormone for the diagnosis of recurrent thyroid cancer. ANZ Journal of Surgery 2005 75 10-20.
20. Brazier J, Usherwood T, Harper R & Thomas K. Deriving a preference-based single index from the UK SF-36 health survey. Journal of Clinical Epidemiology 1998 51 1115-1128.
21. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C & Schlumberger M. Second primary malignancies in thyroid cancer patients. British Journal of Cancer 2003 89 1638-1644.
22. Sant M, Aareleid T, Berrino F, Bielska LM, Carli PM, Faivre J, Grosclaude P, Hedelin G, Matsuda T, Moller H, Moller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santaquilani M, Roazzi P & Lisi D. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Annals of Oncology 2003 14 (Suppl 5) v61-118.
23. Rosario PW, Fagundes TA, Rezende LL, Padrao EL, Borges MAR & Barroso AL. Assessing hypothyroidism in the preparation of patients with thyroid cancer: cardiovascular risk, renal function, drug metabolism, persistence of elevated thyroid-stimulating hormone, and absence from work. The Endocrinologist 2006 16 25-29.
24. Koopmanschap MA & Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996 10 460-466.
25. Maini CL, Sciuto R & Tofani A. TSH suppression by octreotide in differentiated thyroid carcinoma. Clinical Endocrinology 1994 40 335-339.
26. Mazzaferri EL. NCCN thyroid carcinoma practice guidelines. Oncology 1999 13 391-442.
27. Schroeder PR & Ladenson PW Impact of recombinant TSH on quality of life in thyroid carcinoma patients undergonig remnant ablation or diagnostic whole body scanning 2005 13th International Thyroid Congress, Buenos Aires 2005 www.13itc.org/abstracts/poster/pl88.htm.
28. Ware JE Jr, Kosinski M & Dewey JE. How to Score Version 2 of the SF-36 Health Survey, 2nd Edition. Lincoln, RI, USA: Quality Metric Inc. 2006.
29. Mazzaferri EL & Kloos RT. Is diagnostic iodine- 131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? Journal of Clinical Endocrinology and Metabolism 2002 87 1490-1498.
30. Medical Services Advisory Committee recombinant human thyroid-stimulating hormone (rhTSH) - diagnositic agent for use in well-differentiated thyroid cancer 2002 Commonwealth of Australia.
31. Ness RM, Holmes AM, Klein R & Dittus R. Utility valuations for outcome states of colorectal cancer. American Journal of Gastroenterology 1999 94 1650-1657.
32. Coudeville L, Brunot A, Szucs TD & Dervaux B. The economic value of childhood varicella vaccination in France and Germany. Value Health 2005 8 209-222.
33. OECD Employment outlook 2005 Statistical Annex 2005 Available at http://www.oecd.ord/dataoecd/36/30/35024561.pdf.
34. Brown ML, Riley GF, Schussler N & Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Medical Care 2002 40 IV-17.